Candel Therapeutics, Inc. (CADL): Price and Financial Metrics
GET POWR RATINGS... FREE!
CADL Stock Price Chart Interactive Chart >
CADL Price/Volume Stats
| Current price | $2.57 | 52-week high | $5.75 |
| Prev. close | $2.41 | 52-week low | $1.40 |
| Day low | $2.41 | Volume | 7,067 |
| Day high | $2.64 | Avg. volume | 42,928 |
| 50-day MA | $1.95 | Dividend yield | N/A |
| 200-day MA | $2.95 | Market Cap | 74.26M |
Candel Therapeutics, Inc. (CADL) Company Bio
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate, has been engineered for enhanced specificity and tumor cell killing, while minimizing toxicity on healthy tissue and indicated for the treatment of recurrent high-grade glioma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was founded in 1999 and is based in Needham, Massachusetts.
Latest CADL News From Around the Web
Below are the latest news stories about CANDEL THERAPEUTICS INC that investors may wish to consider to help them evaluate CADL as an investment opportunity.
Candel Therapeutics to Participate in Upcoming B. Riley Oncology ConferenceNEEDHAM, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a virtual fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference. Details are as follows: Format: Virtual Fireside Chat Date/Time: Thursday, January 19, 2023, at 11:30 am EST A live webcast of the |
Candel Therapeutics Earnings Perspective: Return On Capital EmployedCandel Therapeutics (NASDAQ: CADL ) brought in sales totaling $31 thousand during Q3 according to data provided by Benzinga Pro . However, earnings decreased 109.4%, resulting in a loss of $8.69 million. Candel Therapeutics collected $31 thousand in revenue during Q2, but reported earnings showed a $4.15 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com |
The Independent Director of Candel Therapeutics, Inc. (NASDAQ:CADL), Joseph Papa, Just Bought A Few More SharesEven if it's not a huge purchase, we think it was good to see that Joseph Papa, the Independent Director of Candel... |
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with CancerUpdated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved progression-free survivalHighlighted effects of a single injection of CAN-3110 in recurrent high-grade glioma (HGG) demonstrating a median overall survival (mOS) of 11.6 monthsDue to promising clinical activity, portfolio decision made to prioritize CAN-3110 in H |
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer.Recent clinical data for CAN-3110 and CAN-2409 in high-grade glioma to be presented.Scientific rationale for the recently announced collaboration with the University of Pennsylvania using Candel’s enLIGHTEN™ discovery platform to be discussed.Premier experts and thought leaders in immunology and oncology to share persp |
CADL Price Returns
| 1-mo | 43.58% |
| 3-mo | 43.58% |
| 6-mo | -25.51% |
| 1-year | -40.09% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 43.58% |
| 2022 | -77.11% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...